[Form 3] Helix Acquisition Corp. II Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

BridgeBio Pharma LLC and its parent BridgeBio Pharma, Inc. reported an initial Form 3 disclosing 13,805,126 shares of common stock of BridgeBio Oncology Therapeutics, Inc. (BBOT) held indirectly. The filing shows two fully vested stock options covering 63,934 and 9,494 shares with exercise prices of $3.83 and $1.02, respectively. Voting and investment power is exercised by the parent, and the filers disclaim individual beneficial ownership except for any pecuniary interest.

Positive

• Material indirect stake disclosed: 13,805,126 shares reported, showing clear ownership position in BBOT
• Options fully vested: 63,934 and 9,494 optioned shares are fully vested, enabling potential future exercise

Negative

• Indirect ownership structure: Voting and investment power is exercised by the parent entity, limiting clarity on individual director control
• Disclaimers of beneficial ownership: The reporting parties disclaim beneficial ownership except for pecuniary interest, which may reduce certainty about active control

Insights

Financial Analyst

TL;DR: Significant indirect stake disclosed; no new transactions or changes to liquidity reported.

The Form 3 documents a sizable indirect stake of 13.8 million shares in BBOT, which is material in absolute terms but the filing does not state percentage ownership or any transfers. The inclusion of two fully vested options signals potential future share issuance if exercised, at exercise prices of $3.83 and $1.02. Because the filing is an initial ownership disclosure rather than a transaction report, its immediate market impact is likely limited.

Corporate Governance Expert

TL;DR: Control is exercised at the parent level and directors disclaim individual ownership.

The report clarifies that voting and investment power over the reported shares is exercised by BridgeBio Pharma, Inc., and that the board members listed disclaim beneficial ownership except for pecuniary interests. That structure is important for governance transparency, confirming indirect ownership and centralized control rather than individual director control over voting rights.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BridgeBio Pharma LLC

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DRIVE, SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13,805,126	D(1)(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(3)	05/18/2030	Common Stock	63,934	$3.83	D
Stock Option (Right to Buy)	(3)	05/18/2030	Common Stock	9,494	$1.02	D

1. Name and Address of Reporting Person^*

BridgeBio Pharma LLC

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DRIVE, SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BridgeBio Pharma, Inc.

(Last) (First) (Middle)

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collective, the BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.

2. (Continued from Footnote 1) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

3. The shares subject to such option are fully vested.

	/s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC	08/18/2025
	/s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma, Inc.	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for BBOT disclose?

The Form 3 disclosed that BridgeBio Pharma LLC and BridgeBio Pharma, Inc. hold 13,805,126 shares of BBOT common stock indirectly and two vested option grants covering 63,934 and 9,494 shares.

Are the stock options mentioned in the filing vested and what are their exercise prices?

Yes, both option grants are fully vested. They cover 63,934 shares at an exercise price of $3.83 and 9,494 shares at an exercise price of $1.02.

Who exercises voting and investment power over the reported BBOT shares?

Voting and investment power over the shares held by BridgeBio Pharma LLC is exercised by its parent, BridgeBio Pharma, Inc., per the filing.

Did the reporting persons claim direct beneficial ownership?

No. The filing states that BridgeBio and the listed directors disclaim beneficial ownership for purposes of Section 16 except to the extent of any pecuniary interest.

When was the event requiring this Form 3 reported?

The Date of Event Requiring Statement shown on the form is 08/11/2025.